INCY 250117 90.00C (INCY250117C90000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

INCY250117C90000

Watchlist

0.35
0.000.00%

15min DelayClose Jan 16 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Wall Street Today: Thursday Earnings Looked a Lot More Mixed, and Philly is Booming
Kevin Travers29minutes ago
Live Stock News: Sideways Trading Market After Big TSMC, UNH Earnings, Philly Economy is Booming
Kevin Travers11:03 ET
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday
MT NewswiresJan 16 09:14 ET
Incyte's and Syndax's Graft Disease Treatment Niktimvo Gets FDA Approval for Vial Sizes
WSJJan 15 18:12 ET
Express News | Incyte Corp - Niktimvo Expected to Be Available in U.S. in Early February
ReutersJan 15 17:34 ET
Express News | Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (Axatilimab-Csfr) 9 Mg and 22 Mg Vial Sizes
ReutersJan 15 17:34 ET

Comments

韭菜变主力

Nov 19, 2024 12:59

$Merck & Co (MRK.US)$ $Incyte (INCY.US)$ is a great company. Buying it would be a good decision, unless Merck massively overpays.

Tynkr Lab

Oct 29, 2024 19:14

Tech Stocks Surge While Dow Falters as U.S. Markets Prepare for Key Data

Click Here: TYNKR LAB™
U.S. stock markets closed with mixed results, reflecting cautious investor sentiment as major tech earnings approached alongside key economic data. $Dow Jones Industrial Average (.DJI.US)$ fell by 0.36%, while $S&P 500 Index (.SPX.US)$ and $Nasdaq Composite Index (.IXIC.US)$ posted gains of 0.16% and 0.81%, respectively. This divergence highlights sector-specific movements and investor positioning ahead ...

🚨 This Week’s PDUFAs:
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...

Trytosaveabit

Aug 14, 2024 16:41

News

$Syndax Pharmaceuticals (SNDX.US)$ $Incyte (INCY.US)$ Reuters
5 mins ago
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (Axatilimab-Csfr) for the Treatment of Chronic Graft-Versus-Host Disease (Gvhd)